{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
USAN:DITIOCADE SODIUM [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:disufenton sodium [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
AstraZeneca developed disufenton (NXY-059), a free radical trapping agent, for the treatment of ischaemic stroke and other brain injuries. Nevertheless, large clinical trial (3306 versus 1722 patients) was neutral, providing no evidence for the efficacy of disufenton sodium in patients with stroke. One study using rat cortical brain slices concluded that NXY-059 improved neuronal survival. However, another study in mouse neuroblastoma cells reported no effect. Another study reported that NXY-059 restored endothelial blood-brain. Histological analyses revealed several therapeutic advantages associated with disufenton sodium treatment following acute acoustic trauma, including reductions in inner and outer hair cell loss; reductions in acute acoustic trauma-induced loss of calretinin-positive afferent nerve fibers in the spiral lamina; and reductions in fibrocyte loss within the spiral ligament. However, AstraZeneca terminated the development program.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Nicoxamat (nicotinohydroxamic acid) is a uricosuric drug that increased urinary excretion of urea and depressed urease activity in the stomach and the colon. Patients receiving nicoxamat showed significant improvement in blood ammonia levels as compared to patients receiving neomycin. In a double-blind clinical trial, 24 patients with the advanced chronic liver disease received 1.2 g of the drug daily. Nicoxamat induced some side effects, such as mild diarrhea, constipation, and anorexia.
Status:
Investigational
Source:
NCT01904487: Phase 1 Interventional Completed Alcoholism
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00312780: Phase 2 Interventional Completed Albuminuria
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Furazolium, an antibacterial agent, was studied for the management of skin infections. However, information about the current use of this drug is not available.
Status:
Investigational
Source:
INN:cevipabulin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Cevipabulin is a synthetic, water-soluble tubulin-binding agent with potential antineoplastic activity. Cevipabulin appears to bind at the vinca-binding site on tubulin but seems to act more similar to taxane-site binding agents in that it enhances tubulin polymerization and does not induce tubulin depolymerization. The disruption in microtubule dynamics may eventually inhibit cell division and reduce cellular growth.
Status:
Investigational
Source:
INN:evacetrapib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Evacetrapib (LY2484595) is a novel benzazepine-based CETP inhibitor that has been developed at Lilly Research Laboratories. Evacetrapib inhibits CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. On 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784).
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Eprovafen is an anti-inflammatory compound.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Eptaloprost is a novel concept PGI2-mimetic, which is designed to be activated to the pharmacologically potent cicaprost via beta-oxidation. Eptaloprost has a significant antimetastatic activity in a spontaneously metastasizing tumor model. Eptaloprost was undergoing phase I clinical trials with Schering AG in Germany for the treatment of cardiovascular disorders.
